2026-10-13

Investor & Scientific Update in Stockholm November 12

Isofol invites investors, shareholders, and other stakeholders to an Investor & Scientific Update in Stockholm on November 12. The principal investigator of the company’s ongoing clinical study, Professor Sebastian Stintzing of Charité – Universitätsmedizin Berlin, will discuss developments in colorectal cancer, current and future treatment options, and the latest results from the ongoing study of arfolitixorin. Professor Frits Peters at the Laboratory Medical Oncology, Amsterdam UMC and the Department of Biochemistry, Medical University of Gdansk, will provide the pharmacological background regarding the study’s optimized dosing regimen and explain why it is expected to further enhance the efficacy of arfolitixorin.

The meeting will also include an open Q&A session led by analysts from ABG Sundal Collier and Redeye, as well as presentations by Dr. Roger Tell, Chief Medical Officer, and Petter Segelman Lindqvist, Chief Executive Officer. Following the meeting, there will be an opportunity to meet and speak with members of Isofol’s Board of Directors and management team.

On November 13, a follow-up investor meeting will be held in Gothenburg to present and discuss the key messages from the Stockholm meeting.